We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Bridgepoint Development Capital to Acquire Quotient Clinical

News   Dec 11, 2013

 
Bridgepoint Development Capital to Acquire Quotient Clinical
 
 
Advertisement
 

RELATED ARTICLES

Recreating Nature: Chemists Create Synthetic Version of Natural Anti-Cancer Agent

News

Scripps Research chemists Hans Renata, PhD, and Alexander Adibekian, PhD, have discovered a way to efficiently create a synthetic version of a valuable natural compound called cepafungin I, which has shown promise as an anti-cancer agent.

READ MORE

Wuhan COVID-19 Vaccine Trials Show Early Positive Results, Moving Forward to Phase 3 Testing

News

The adenovirus type-5-vectored COVID-19 vaccine was shown to be safe and induced significant immune responses in the majority of recipients after a single immunization.

READ MORE

Team Screens Millions of Active Substances Against SARS-CoV-2

News

Researchers are screening millions of molecules in order to find those blocking interactions on SARS-CoV-2, to identify those that can be used therapeutically.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE